Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Treasury Shares (2021 - 2025)

Rani Therapeutics Holdings has reported Treasury Shares over the past 5 years, most recently at $348702.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $348702.0 for Q4 2025, up 10606.23% from a year ago — trailing twelve months through Dec 2025 was $348702.0 (up 10606.23% YoY), and the annual figure for FY2025 was $348702.0, up 10606.23%.
  • Treasury Shares for Q4 2025 was $348702.0 at Rani Therapeutics Holdings, down from $416305.0 in the prior quarter.
  • Over the last five years, Treasury Shares for RANI hit a ceiling of $996500.0 in Q1 2022 and a floor of $3257.0 in Q4 2024.
  • Median Treasury Shares over the past 5 years was $596500.0 (2021), compared with a mean of $497100.3.
  • Biggest five-year swings in Treasury Shares: crashed 94.95% in 2023 and later soared 10606.23% in 2025.
  • Rani Therapeutics Holdings' Treasury Shares stood at $596500.0 in 2021, then grew by 11.57% to $665500.0 in 2022, then crashed by 94.95% to $33586.0 in 2023, then tumbled by 90.3% to $3257.0 in 2024, then soared by 10606.23% to $348702.0 in 2025.
  • The last three reported values for Treasury Shares were $348702.0 (Q4 2025), $416305.0 (Q3 2025), and $485083.0 (Q2 2025) per Business Quant data.